Videos

1. CellCube® System Protocol 3/14/2025

   The Corning CellCube system enables large-scale adherent cell culture with uniform laminar flow, optimizing growth. Its closed system design ensures aseptic scalability with AseptiQuick® connectors.

2. Corning Life Sciences: Your Preferred Fetal Bovine Serum Supplier 3/14/2025

   Corning offers standard and custom cell culture media, vessels, and surfaces to support all growth stages. A vertically integrated supply chain ensures reliability and quality.

3. Secure Your Serum Supply 2/18/2025

   Ensure uninterrupted cell culture success with reliable, high-quality animal-derived serum, including FBS, with consistent performance. Learn how to secure your supply.

4. Your Preferred Fetal Bovine Serum Supplier 2/6/2025

   As part of our complete cell culture offering, Corning’s comprehensive line of standard and custom cell culture media helps create an optimal environment for all stages of cell culture growth and scaling.

5. Streamline Your Cell Culture With Corning Closed System CellSTACK Vessels 8/28/2024

   Corning Closed System solutions for CellSTACK vessels streamline the cell culture process while reducing the risk of contamination.

6. Audience Q&A 3/8/2023

   During each Cell & Gene Live, our audience can submit real-time questions for our expert panelists. Watch and listen as Michael Blackton and John Lee provide detailed, insightful responses to our audience questions on everything from how changing from a lab-based adherent protocol to suspension scalable protocol improved the cell product to whether a container with lesser cells, identical cell density, and composition be used for establishing stability for cell therapy products, and much more.

7. Design And Execution Of Comparability Studies 3/8/2023

   During Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee provided detail on how successful comparability studies are designed and executed. They covered the in-process and release testing requirements, as well as the common and uncommon pit falls that have been encountered.

8. Donor-To-Donor Variability 3/8/2023

   For cell-based products, donor-to-donor variability is the primary source of complexity associated with establishing product comparability. In this segment of Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee cover why donor-to-donor variability is an on-going challenge and potential solutions.

9. How The Process Influences The Product 3/8/2023

   Here, during this segment of Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee highlight the various ways to demonstrate our understanding of how the process influences the product, as well as how the product’s structure influences its clinical function.

10. Increased Comparability Burden During Clinical Trials 3/8/2023

    As a therapy proceeds through Phases I / II and into Phase III clinical trials, the comparability burden increases. As the body of knowledge increases, the comparability burden evolves. Some tests may be removed while others are added, and assumptions may change with data. In this segment of Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee break down the comparability requirements from early- to late-stage programs.